Keyphrases
Acquired Resistance
18%
Active Components
37%
Adverse Effects
37%
Anticancer Drugs
100%
Anticancer siRNA
37%
Ascitic Fluid
18%
B-cell Lymphoma 2 (Bcl-2)
24%
Cancer Cell Death
18%
Cancer Cell Resistance
18%
Cancer Cells
37%
Cancer Imaging
100%
Cancer Treatment
100%
Cancer-specific
18%
Carboplatin
18%
Cell Death
18%
Cell Death Induction
5%
Cell Resistance
5%
Cell-to-cell
18%
Cellular Uptake
18%
Chemotherapeutic Treatment
18%
Chemotherapy
24%
Chemotherapy Side Effects
18%
Cisplatin
24%
Cluster of Differentiation 44 (CD44)
24%
Drug Imaging
18%
Drug Resistance
18%
Effective Treatment
5%
Existing Drugs
18%
Fluorescent Dye
18%
Hormone Peptide
18%
Hydroxyl-terminated
18%
Imaging Agents
18%
In Cancer
18%
Inducer
18%
Intrinsic Resistance
18%
Local Administration
18%
Luteinizing Hormone
18%
Malignant Ascites
18%
Mechanism of Action
5%
Metastasis
18%
Metastatic Cells
18%
Multidrug Resistance Protein 1 (MDR1)
24%
Multidrug-resistant
56%
Multifunctional Nanocarriers
5%
Nano-drug Delivery System
56%
Nanocarrier-based Drug Delivery Systems
5%
Nanocarriers
18%
Nanotechnology
43%
Nanotherapeutics
100%
Nude Mice
18%
Ovarian Cancer
43%
Ovarian Cancer Cells
37%
Ovarian Carcinoma
18%
Ovarian Metastasis
43%
Ovarian Tumor
18%
Paclitaxel
24%
PAMAM-OH
18%
Peritoneal Metastasis
24%
Polyamidoamine (PAMAM)
18%
Primary Malignant
18%
Primary Ovarian Cancer
43%
Primary Tumor
37%
Public Health
5%
Quaternized
18%
Small Interfering RNA (siRNA)
81%
Specific Targeting
18%
Targeted Drugs
18%
Targeting Moieties
37%
Treatment Efficacy
18%
Treatment Side Effects
5%
Tumor Cells
18%
Tumor Targeting
18%
Medicine and Dentistry
Anticancer Drug
68%
Anticarcinogen
15%
Cancer
15%
Cancer Cell
79%
Cancer Therapy
100%
Carboplatin
15%
Cell Death
36%
Chemotherapy
15%
Cisplatin
20%
Dendrimer
15%
Drug Delivery System
68%
Drug Resistance
15%
Fluorescent Dye
15%
Gonadorelin
15%
Imaging Agent
15%
Krukenberg Tumor
15%
Malignant Ascites
15%
Messenger RNA
36%
Metastatic Carcinoma
36%
Multidrug Resistance Protein 1
20%
Nanocarrier
20%
Ovarian Cancer
88%
Ovarian Cancer Cell Line
15%
Ovarian Tumor
15%
Ovary Metastasis
15%
Paclitaxel
20%
Peptide Hormone
15%
Polyamidoamine
31%
Primary Tumor
31%
Side Effect
52%
Small Interfering RNA
100%
Specific Tumor
15%
Tumor Cell
15%
Pharmacology, Toxicology and Pharmaceutical Science
Anticancer Drug
65%
Anticarcinogen
15%
Carboplatin
15%
Chemotherapy
34%
Cisplatin
19%
Dendrimer
15%
Drug Delivery System
65%
Drug Resistance
15%
Fluorescent Dye
15%
Gonadorelin
15%
Malignant Ascites
15%
Malignant Neoplasm
100%
Messenger RNA
34%
Multidrug Resistance Protein 1
19%
Nanocarrier
19%
Neoplasm
15%
Nude Mouse
15%
Ovary Cancer
100%
Ovary Carcinoma
15%
Ovary Metastasis
15%
Ovary Tumor
15%
Paclitaxel
19%
Peptide Hormone
15%
Poly(amidoamine)
30%
Primary Tumor
30%
Side Effect
50%
Small Interfering RNA
95%